December 20, 2018 09:13 AM EST
R&D

Mer­ck KGaA hands off its CAR-T R&D op­er­a­tions to In­trex­on in $175M deal

John Carroll

Editor & Founder

Mer­ck KGaA is bow­ing out of the CAR-T de­vel­op­ment busi­ness, hand­ing over its rights to In­trex­on $XON in ex­change for $150 mil­lion batch of stock …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times